ArticleBMC cancer2018

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.

Lorenzo Tosco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.